Britain and America have secured a key commercial pact that will keep no import taxes on British medicine exports going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the NHS. This move ensures that tariffs on these crucial products will stay at nothing for a timeframe of three years.
This agreement follows recent statements to significantly raise import taxes on branded pharmaceutical imports, with potential rates floated reaching one hundred percent.
"This deal between the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed balance to transatlantic drug exports," a statement noted.
Economic Importance
Drugs represent one of the UK's most significant goods shipped to the America, which is clearly the biggest destination for large UK drugmakers.
Statistics indicate that in the year leading up to September, the UK exported medicines valued at over eleven billion pounds to the US. This value made up nearly one-fifth of British export trade in that period.
"This guarantee protects employment, boosts capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a government official commented.
Specific UK Commitments
The pact includes several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
The deal follows a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that American patients were charged several times more for the identical medicines than people in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been directed toward American operations.
The Science Minister acknowledged that the NHS had to invest a greater share on treatments, noting that its spending on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
